Access Official Technical PDF

Share Summary:LinkedInEmail

Maine employer drug testing is governed by a state law designed to balance employee privacy, proper testing procedures, workplace protections and access to treatment. The Maine Department of Labor’s 2018 report provides a detailed snapshot of testing conducted under that law. For industrial employers and operations leaders, the findings offer useful context—but they are not a direct measure of substance use across Maine’s entire workforce.

The report covers employers with policies approved under Maine law and testing activity reported for 2018. It excludes testing conducted under federal programs and certain employers exempted from the state law. Those boundaries matter when using the figures to inform workforce policies or safety discussions.

Maine employer drug testing: what the report covers

Employers seeking to test current or prospective employees under Maine law must submit a substance abuse testing policy to the Maine Department of Labor (MDOL). Testing cannot begin until the policy is approved and employees receive proper notice. Employers with more than 20 full-time employees must also have a functioning Employee Assistance Program (EAP) before testing employees, according to the report.

Several state agencies share responsibilities. The MDOL Bureau of Labor Standards reviews policies, collects annual testing reports and analyzes the data. The Maine Department of Health and Human Services is responsible for licensing laboratories that employers may use, and its Division of Licensing and Regulatory Services certifies EAPs.

Employers with active approved policies are required to report testing activity annually. The survey records tests by category, substances tested for and positive results reported by laboratories. In 2018, 552 employers had active policies, while 432 responded to the survey within the reporting period. Of the responding employers, 110 reported no testing that year.

Testing types and 2018 results

The report groups tests into three categories, each reflecting a different point in the employment relationship or a different basis for testing:

  • Applicant testing: Testing before an individual is hired, after an employment offer or placement on an eligibility roster.
  • Probable cause testing: Testing of an existing employee when reasonable grounds exist to believe the person may be under the influence of a substance of abuse.
  • Random or arbitrary testing: Random selection gives employees an equal chance of selection within the applicable group. Arbitrary testing is based on criteria unrelated to substance abuse, such as a hire-date anniversary or a client requirement.

Across all reported categories, employers conducted 25,113 tests and reported 1,455 positive results, a rate of 5.8%. Applicant testing accounted for the vast majority of activity: 23,999 tests, with 1,399 positive results, also 5.8%. There were 1,079 random or arbitrary tests, with 38 positives, or 3.5%.

Probable cause testing produced a much higher reported positive percentage: 18 positive results from 35 tests, or 51.4%. That figure should be read in light of the small number of tests. A percentage based on 35 tests can change substantially with only a few additional results, and the category is specifically limited to situations where reasonable grounds exist.

Cannabinoids dominated reported positive results

Cannabinoids accounted for 1,309 of the 1,455 positive results across all test types—90% of reported positives. The overall positive rate for tests that included cannabinoids was 5.74%. The next-largest shares of positives were for amphetamines (3.9%) and cocaine (2.9%). The report notes that many employers used a common five-panel test covering cannabinoids, amphetamines, cocaine, opiates and phencyclidine.

These figures describe laboratory results as reported under the survey, not every case in which a person initially tested positive. The report excludes instances where an employer allowed a positive result to be reported as negative after the individual validated a prescription or medical marijuana registration card authorized by a healthcare professional. It also notes that invalid tests can involve issues such as specimen collection, chain of custody, security or testing procedures, and may sometimes be repeated.

Industry patterns require careful interpretation

Among the reported industries, Services recorded the most tests, with 13,986, followed by Manufacturing, with 4,462, and Trade, with 4,225. Manufacturing reported 271 positives, or 6.1% of its tests. Within that broad category, reported rates varied: Food Products was 14.5%, Plastics and Rubber was 13.1%, and Other Manufacturing was 4.8%.

These comparisons are descriptive, not explanations of why results differed. The report does not establish causes, and industry groupings can combine workplaces with different roles, testing policies and workforces. A percentage should not be treated as a measure of safety performance or as a prediction for an individual facility.

What the results mean for industrial employers

For manufacturers, utilities, construction firms and other industrial organizations, the report is most useful as a policy and data-interpretation reference. It shows why employers should distinguish between applicant, probable cause and random or arbitrary testing rather than combining the categories without context. It also highlights that a testing program is not simply a laboratory process: under Maine law, policy approval, employee notice, laboratory requirements and—in some cases—an EAP are part of the framework.

When reviewing workplace drug-testing policies, decision-makers should keep several limits in view:

  • The results cover testing reported under Maine law, not federal testing programs or all employers.
  • Not all employers with active policies responded to the annual survey.
  • Small test counts can make percentages especially sensitive to individual results.
  • A positive test rate alone does not explain underlying causes or establish operational risk.

Conclusion: use the data as context, not a benchmark

Maine’s 2018 report documents 25,113 tests and a 5.8% overall positive rate among activity covered by the state reporting system. Applicant tests made up most of the volume, cannabinoids represented most positive results, and rates varied across testing categories and industries. For industrial employers, the practical lesson is to interpret these figures within their scope, maintain clear and compliant policies, and avoid treating statewide results as a substitute for site-specific workforce and safety decisions.

Access Official Technical PDF

About The Author